The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

1Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality globally and usually presents in patients with chronic liver inflammation associated with viral infection, alcohol overuse, or metabolic syndrome., Significant progress has been made in HCC prevention, diagnosis and treatment in the past. However, more than 50% of all HCC patients have a diagnosis at an advanced stage (Barcelona Clinic Liver Cancer stage B or higher), and 70% of patients relapse within the first 5 years of initial treatment. Early HCC is often resectable, but advanced HCC often requires sorafenib for systemic treatment in addition to local treatment with ablation, transarterial chemoembolization, or external irradiation.,

2In a groundbreaking study, sorafenib, a multiple-target tyrosine kinase inhibitor (TKI) exhibited antiangiogenesis and antiproliferation effects and extended total median survival in advanced HCC patients. Sorafenib suppresses tumor cell proliferation by inhibiting Raf-1, B-Raf, and kinase activity in the Ras/Raf/MEK/ERK signaling pathways. In addition, sorafenib is capable of targeting platelet-derived growth factor receptor (PDGFR-β), vascular endothelial growth factor receptor (VEGFR) 2, hepatocyte factor receptor (c-KIT), and other proteins to inhibit tumor angiogenesis. In two significant clinical trials, Asia-Pacific and Sorafenib HCC assessment randomized protocol (SHARP), sorafenib was effective in improving the outcomes of HCC patients in the late stage, initiating a period of robust clinical research., Since 2017, one large phase III trial has suggested noninferiority of lenvatinib compared with sorafenib in the first-line setting. Furthermore, regorafenib, cabozantinib, and ramucirumab have received approval as second-line treatments after sorafenib.– Checkpoint inhibitors have also opened new strategies for the treatment of HCC., Recently reported results from the IMbrave150 study (NCT03434379) show potential for the combination of atezolizumab with bevacizumab to expand the treatment options in first-line therapy for HCC. However, immunotherapy for HCC has not yet been approved in China or Germany. Sorafenib remains a cornerstone treatment in HCC that is supported by robust evidence and clinical experience.

3Only approximately 30% of patients can benefit from sorafenib, and this population usually acquires drug resistance within 6 months. Adverse events identified in patients administered sorafenib mainly included gastrointestinal, physical or skin diseases (e.g., hand and foot skin reactions, weight loss, and diarrhea). In serious cases, sorafenib can cause high blood pressure and abdominal pain, leading to treatment discontinuation. Accordingly, the sorafenib resistance mechanisms should be clarified. Recent studies suggest a role of epigenetics, transport processes, regulated cell death, and the tumor microenvironment in the initiation and development of sorafenib resistance in HCC. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients.

4Epigenetic modifications can change the expression states of genes without changing DNA sequences, and some modifications can be inherited. In some cases, epigenetic changes are dynamic and respond to environmental stimuli. Epigenetic mechanisms regulate different physiological processes that occur in living organisms, including cell proliferation and differentiation., A deeper understanding of epigenetic modifications associated with HCC could provide the basis for developing innovative approaches to treat this disease. In this context, we will describe the different types of epigenetic mechanisms and their involvement in the resistance of HCC to sorafenib (Table 1).–

5Increasing evidence indicates that noncoding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), are critical for the development of sorafenib resistance in HCC (Fig. 1). Small nucleolar RNA host gene 3 (SNHG3) had significantly higher expression in highly metastatic HCC cells than in poorly metastatic HCC cells and induced epithelial–mesenchymal transition (EMT) through miR-128/CD151 cascade activation to produce sorafenib resistance. SNHG16 was reported to be upregulated in HepG2 sorafenib-resistant (SR) cells, and SNHG16 knockdown increased the sensitivity of HepG2 SR cells to sorafenib in vitro and in vivo. Mechanistic studies indicated that SNHG16 could be an endogenous sponge for miR-140-5p in HepG2 cells. Overexpression of miR-140-5p also made HepG2 SR cells more susceptible to sorafenib, and the influences exerted by SNHG16 knockdown on sorafenib resistance might be inhibited by miR-140-5p inhibitors. Overexpression of miR-591 has been reported to inhibit colony formation, as well as drug resistance, including sorafenib resistance, through the inhibition of the expression of far upstream elemental binding protein 2 (FBP2) via the phosphoinositide 3 kinase/Akt/mammalian target of the rapamycin axis. MiR-622 is significantly downregulated in HCC and functionally targets Kirsten rat sarcoma (KRAS), whose inhibition significantly inhibits RAF/ERK and PI3K/AKT signaling and resensitizes sorafenib-resistant cells. These studies indicate that ncRNAs may represent a medical treatment approach to overcome sorafenib resistance in HCC. However, further research is needed to determine whether ncRNAs are drivers or passengers in tumor progression, as numerous ncRNAs have been reported to be dysregulated in cancer progression. In addition, current studies have focused only on the role of lncRNAs as miRNA sponges in regulating target gene expression and mediating sorafenib resistance in HCC. Previous research indicates that lncRNAs have more mechanisms, such as binding to proteins regulating protein translation, interfering with the expression of genes encoding adjacent proteins, and forming complexes with proteins to regulate gene transcription, which are areas in need of further exploration., Further studies of clinical trials are urgently needed to promote ncRNA-based therapeutic interventions beneficial to HCC patients, which may offer treatment avenues for sorafenib resistance.

6Methylation refers to the process of catalytically transferring methyl groups from active methyl compounds (such as S-adenosylmethionine) to other compounds. Examples consist of RNA methylation, histone methylation, and DNA methylation. Aberrant methylation causes gene expression to be changed, resulting in cancerous features. Wang et al. reported that the MORC2-NF2/KIBRA axis is critical to maintain sorafenib resistance and oncogenicity of HCC cells in vitro and in nude mice. MORC2 complexes with DNA methyltransferase 3A (DNMT3A) on the promoters of NF2 and KIBRA, causing DNA hypermethylation and transcriptional inhibition. Accordingly, under physiological and pathological conditions, NF2 and KIBRA are key targets of MORC2 for the regulation of fusion-induced Hippo signaling activation and contact inhibition of cell growth. Abeni et al. used medical chip technology to find 1230 differentially methylated genes in sorafenib-treated HA22T/VGH cells. After sorafenib treatment, oncogenes tend to be hypermethylated, while tumor suppressor genes tend to be hypomethylated. In addition, the lncRNA H19 is an example of maternal expression and epigenetic regulation of imprinted gene products and is believed to promote or inhibit tumors. In sorafenib-resistant cell lines, the promoter methylation of the H19 gene differs noticeably from that in sensitive cells. Overexpression of H19 sensitizes sorafenib-resistant cells by reducing cell proliferation after sorafenib treatment. A model of H19 knockout mice suggested that H19 promoted tumor progression and tumor cell proliferation after treatment with the carcinogen diethylnitrosamine (DEN), while administration of insulin-like growth factor 2 (IGF2) had no effect. Therefore, H19 may be a target for future strategies to overcome sorafenib resistance in HCC. Together, this evidence suggests that sorafenib may influence the methylation levels of cancer-related genes in HCC, which are valuable in tracing sorafenib resistance.

7Sorafenib resistance involves ATP binding box (ABC) transporters, which reduce the effectiveness of chemotherapy by pulling drugs out of cancer cells and negatively affect the outcomes of anticancer therapies., In addition, exosomes are carriers of intercellular information and regulators of the tumor microenvironment. In normal cells, exosomes remove adverse biomolecules, but this mechanism may be hijacked in cancer cells. For example, drug-resistant cancer cells can encapsulate therapeutic drugs in exosomes and transport them out of tumor cells., The mechanisms of the transport process and sorafenib resistance in HCC are reviewed below (Table 2).,,–

8Several TKIs, including sorafenib, were found to interact with ABC transporters. Such findings reveal a highly sophisticated situation in which TKIs are likely to act as substrates or inhibitors, depending on specific pump expression and the type of drug coadministered, its affinity for transporters, and its concentration. The repositioning of TKIs as ABC transporter antagonists opens up new avenues for anticancer therapy and clinical strategies aimed at counteracting drug resistance. Di Giacomo et al. investigated the ability of CRYO (the natural sesquiterpene component of many essential oils) to inhibit ABC pumps and improve the response of HCC cells to sorafenib at nontoxic doses. They obtained a clonal subfamily from human HCC cells exhibiting increased multidrug resistance (MDR) related to upregulation of MRP1 and MRP2. In addition, CRYO restrained sorafenib degradation, facilitated its intracellular accumulation and strengthened its cytotoxic response. Another study reported that COP9 signaling corset 5 (CSN5) was associated with sorafenib resistance in HepG2/S HCC cells. After CSN5 silencing, resistance to sorafenib was reversed, and several resistance-related proteins (including ABCB1, ABCC2, and ABCG2) were downregulated. Furthermore, ABCC1-3 expression increased in SR cells. Enhanced SR cell migration and invasion and an increased ratio of CD44+ to CD44+ CD133+ cells were observed in SR cells.

9Exosomes, which are small extracellular vesicles (EVs), contribute to cell-to-cell communication and have emerged as a therapeutic target.– LincRNA-VLDLR (linc-VLDLR) showed significant upregulation in malignant liver cells. Exposure of HCC cells to various anticancer agents (e.g., sorafenib) increased the expression of linc-VLDLR in cells and in EVs released from these cells. Incubation with EVs downregulated chemotherapy-triggered cell death and increased linc-VLDLR expression in recipient cells. In addition, knockdown of linc-VLDLR reduced ABCG2 (ATP binding cassette, subfamily G member 2) expression, and overexpression of this protein reduced the effect of linc-VLDLR knockdown on sorafenib-induced cell death. Apart from lncRNAs, miRNAs can also be carried in exosomes, and miR-122-transfected adipose tissue mesenchymal stem cells (AMSCs) have been shown to efficiently package miR-122 in secreted exosomes, probably mediating AMSC and HCC cell miR-122-related communication processes, thus making HCC cells sensitive to sorafenib by altering the expression of miR-122 target genes. Intratumor injection of miR-122-exo noticeably improved the antitumor performance of sorafenib in HCC in vivo. Li et al. showed that the combination of si-GRP78-modified exosomes and sorafenib could target GRP78 in HCC cells and restrain cancer cells from growing and invading. Therefore, si-GRP78-altered exosomes can sensitize sorafenib-resistant cancer cells to reverse drug resistance. Dendritic cells (DCs) are critical to both primary and secondary immune responses; thus, DC-derived exosomes are candidates for specific cancer treatment. Shi et al. found that regulatory T cells in tumor tissues and sorafenib treatment of HCC mice in situ increased programmed death ligand 1 (PD-L1) expression. When DCs were pulsed with exosomes from tumor cells, the number of regulatory T cells decreased, and the number of CD8+ T cells increased. When anti-programmed death receptor-1 (PD-1) antibody (PD-1 Ab) was added, the exhausted CD8+ T cells were restored, while the regulatory T cell number remained unchanged. Because exosomes are involved in the development of many diseases, researchers have used exosomes as a therapeutic strategy, in which exosomes are loaded with therapeutic agents such as functional proteins, ncRNAs, and chemotherapy drugs (Fig. 2). The resistance mechanisms involving exosome-mediated crosstalk need to be addressed by future therapeutic strategies for advanced-stage HCC.

10RCD is used to describe the death of cells originating from the intracellular or extracellular microenvironment via molecular mechanisms when other adaptive responses cannot restore cell homeostasis, and RCD can be divided into different categories, including apoptosis, autophagic cell death, proptosis, ferroptosis, etc., according to the different mechanisms., It has been reported that RCD, especially autophagy and ferroptosis, is involved in sorafenib resistance in HCC (Table 3).–

11Autophagy is an important process leading to intracellular material turnover in eukaryotes. Some of the damaged proteins or organelles in this process are encapsulated in bilayered autophagic vesicles and sent to lysosomes for degradation and recycling., The effect exerted by autophagy in cancer cells plays a double-edged sword., Basic autophagy is a cancer suppressor that maintains genomic stability in normal cells, whereas activated autophagy promotes the survival of cancer cells under stress once cancer occurs. Autophagy is also thought to be an important mechanism for drug resistance by supporting the survival of tumor cells in the case of therapeutic and metabolic stress. Therefore, it is necessary to determine how to control cell growth, apoptosis and sorafenib resistance by changing autophagy levels, which could possibly improve the efficacy of sorafenib and the treatment of HCC. Activation of Akt is considered to account for the mediation of acquired resistance to sorafenib. Zhai et al. found that Akt inhibition reversed acquired resistance to sorafenib by transforming autophagy from a cell-protective effect to a system that promotes cell death. Moreover, sorafenib effectively reversed the activation of metformin-induced mTORC2 and enhanced the inhibitory effect of metformin on the mTORC1 and MAPK pathways in HCC cells. Pharmacological inhibition of autophagy sensitized HCC cells to apoptosis induced by metformin and sorafenib. Studies have also shown that patients exhibiting high ATG7 expression and an active autophagy state have poor prognosis after sorafenib treatment. Due to different autophagy responses to sorafenib, different HCC cell lines have different sensitivities to sorafenib. Animal models are seen as key tools in cancer research. A recent study has shown that ADRB2 signaling restrained autophagy through disruption of the Beclin1/VPS34/Atg14 complex in an AKT-dependent manner, causing HIF1α stabilization, reprogramming of glucose metabolism in HCC cells, and sorafenib resistance in DEN-induced HCC mouse models. Despite ample evidence that targeted autophagy processes represent potential therapeutic interventions for HCC (Fig. 3), there are many unresolved issues related to autophagy in sorafenib resistance. How do we selectively target autophagy mechanisms? How do we balance the dual effects of autophagy? What determines the threshold for autophagy to change from a survival mechanism to one that promotes apoptosis or autophagic death? The answers to these questions need to be further elucidated through research.

12Ferroptosis refers to a nonapoptotic, RCD procedure involving the abnormal metabolism of lipid oxides in cells catalyzed by iron ions or iron enzymes and has been identified recently. In this process, various inducers break the cell redox balance and produce considerable lipid peroxidation products, thereby triggering cell death. A growing body of research shows that the relationships between ferroptosis and cancer are significantly complex and that ferroptosis holds promise as a novel cancer treatment. The fact that sorafenib induces ferroptosis, which promotes sorafenib resistance adds to the complexity of sorafenib’s antitumor mechanism in HCC (Fig. 4). A recent study reported that the depletion of intracellular iron stores realized through the iron chelator deferoxamine (DFX) strikingly protected HCC cells from the cytotoxic effects of sorafenib. Moreover, they identified that DFX did not prevent sorafenib from reaching its intracellular target kinases. Instead, the depletion of intracellular iron stores prevented sorafenib from inducing oxidative stress in HCC cells. Beyond that, Lachaier et al. reported that sorafenib induced ferroptosis in different cancer cell lines. Compared to other kinase inhibitors, sorafenib was the only drug that displayed ferroptotic efficacy. From a mechanism of action perspective, Sun et al. found that metallothionein (MT)-1G was a critical regulator and promising therapeutic target of sorafenib resistance in human HCC. The expression of MT-1G messenger RNA and protein was noticeably triggered by sorafenib but not by other clinically relevant kinase inhibitors. The activation of the transcription factor nuclear factor erythroid 2-related factor 2, but not of p53 and hypoxia-inducible factor 1-alpha, was critical to induce MT-1G expression following sorafenib treatment. The molecular mechanisms of MT-1G in sorafenib resistance participate in the suppression of ferroptosis, a novel form of altered cell death. Knockdown of MT-1G by RNA interference increased glutathione depletion and lipid peroxidation, which contributed to sorafenib-induced ferroptosis. According to another study, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human hepatic stellate cells (HSCs) from the collected human liver tissues. In conclusion, sorafenib-induced ferroptosis may be an effective mechanism for inducing HCC cell death, regardless of its inhibitory effect on kinases.

13Cancer metastasis, invasion and growth are affected by the tumor microenvironment, which is comprised of various nonmalignant stromal cells. A sophisticated and multidirectional interplay between immune or nonimmune stromal cells and tumor cells during HCC development and progression has been recently shown (Table 4).–

14Hypoxia in HCC drives angiogenesis through a vascular endothelial growth factor (VEGF)-producing process and hypoxia-inducible factor 1 (HIF-1α) activation. Therefore, the antiangiogenic effect of sorafenib results from blockade of the HIF-1α/VEGF pathway., Sorafenib suppresses the synthesis of hypoxia-inducible factor 1 (HIF-1α), resulting in a decrease in VEGF expression and tumor angiogenesis in HCC. In addition, acquired sorafenib resistance and an anoxic microenvironment show an interesting correlation. Continuous sorafenib treatment results in inhibition of the tumor’s antiangiogenic activity and subsequent hypoxia within the tumor, which facilitates the selection of resistant cell clones to adapt to oxygen and nutrition deficits, thereby limiting the efficiency of sorafenib. A study by Liang et al. reported that hypoxia induced by continued sorafenib treatment conferred sorafenib resistance in HCC via HIF-1α and NF-κB activation. EF24, a molecule having structural similarity to curcumin, overturned sorafenib resistance via VHL-dependent HIF-1α degradation and NF-κB inactivation. Prieto-Domínguez et al. found that the coadministration of melatonin and sorafenib decreased the expression of HIF-1α mitophagy targets and restrained the formation of autophagosomes and subsequent colocalization of mitochondria and lysosomes. Melatonin enhanced sensitivity to sorafenib in Hep3B cells and blocked the synthesis of HIF-1α, thus preventing the protective cell phagocytosis caused by the hypoxic microenvironment, which is an important part of the multifactor mechanism responsible for the failure of chemotherapy. In addition, miR-338-3p was shown to inhibit HCC tumor growth and sensitize HCC cells to sorafenib by downregulating HIF-1α. Galectin-1 has been reported as a predictive marker of sorafenib resistance and a downstream target of the AKT/mTOR/HIF-1α signaling pathway. Considering the feedback system between HIF-1α and HIF-2α subunits, we believe that sorafenib treatment is likely to upregulate HIF-2α by inhibiting HIF-1α, enhancing sorafenib resistance and tumor growth., It has also been confirmed that the increase in HIF-2α triggered by sorafenib contributes to resistance through the activation of the TGF-α/EGFR pathway. Another study found that the HIF-2α inhibitor PT-2385 significantly enhanced sorafenib efficacy by suppressing HIF-2α, increasing androgen receptor (AR) and suppressing downstream pSTAT3/pAKT/pERK pathways. These studies endorse the existing relationship between high HIF expression and resistance to sorafenib (Fig. 5), demonstrating that hypoxia evidently impacts sorafenib therapy and suggesting that inducing hypoxia is a promising approach to overcoming resistance.

15Tumor immune escape has garnered interest in the development of tumor immunotherapy strategies, which have proved to be effective for some malignant neoplasms. Tumor-associated macrophages (TAMs) restrain antitumor immunity and facilitate tumor progression by expressing cytokines and chemokines. Current clinical trials of therapeutic drugs that promote phagocytosis or inhibit survival, proliferation, transport or polarization of TAMs have shown improved tumor prognosis. In HCC, Yao et al. reported that a natural product from Abies georgei, which is termed 747 and is related in structure to kaempferol, exhibited sensitivity and selectivity as a CCR2 antagonist. 747 enhanced the therapeutic efficacy of low-dose sorafenib without obvious toxicity by elevating the numbers of intratumoral CD8+ T cells and increasing the death of tumor cells. Chen et al. found that sorafenib increased the numbers of F4/80+ TAMs and CD11b+Gr-1+ and CD45+CXCR4+ myeloid cells in both HCA-1 and JHH-7 HCC models. Moreover, sorafenib treatment resulted in an increase in the fraction of tumor-infiltrating CD4+CD25+FoxP3+ regulatory T cells (Tregs) in HCA-1 tumors. Using AMD3100 to inhibit the stromal cell-derived 1 receptor (C–X–C receptor type 4 or CXCR4) can prevent polarization of the immunosuppressive microenvironment after sorafenib treatment, inhibit tumor growth, reduce lung metastasis, and improve survival. In addition, studies have demonstrated that M2, but not M1, macrophages maintain tumor growth and metastasis by secreting hepatocyte growth factor (HGF), thereby significantly increasing tumor resistance to sorafenib. HGF activates the HGF/c-Met, ERK1/2/MAPK and PI3K/AKT pathways in tumor cells. In vivo M2 tumor-associated macrophages accumulate more in sorafenib-resistant tumors than in sorafenib-sensitive tumors and produce large amounts of HGF. HGF can attract more macrophages from the surrounding area and regulate M2 macrophage distribution and feedback to enhance the sorafenib resistance of liver cancer. Neutrophils are capable of promoting or inhibiting tumor progression via the release of cytokines, which is determined by the tumor microenvironment. Factors generated by tumor-associated neutrophils (TANs) and their effects on tumor progression have not been elucidated. Zhou and colleagues explored the roles of TANs in the progression of HCC using cell lines and immune cells isolated from patients. They found that in tumor-bearing mice, sorafenib increased the number of TANs as well as CCL2 and CCL17 levels in the tumor. HCC tissues treated with sorafenib before surgery contained more TANs than tissues not treated with sorafenib. In mice, TAN depletion and sorafenib administration suppressed tumor growth and neovascularization more significantly than sorafenib administration alone. Phosphorylated extracellular signaling-regulated kinase (pERK) has been proposed as a marker for predicting the response to sorafenib in HCC, but clinical support is mixed or even contradictory. Chen et al. found that the pERK expression level varied in different patients with liver nodules. Mouse and human HCC samples with low pERK expression showed noticeable increases in intratumor CD8+ cytotoxic T lymphocytes with robust inflammatory infiltrating cells and expression of PD-1, suggesting that anti-PD-1 immunotherapy may supplement sorafenib in HCC patients by targeting sorafenib-resistant cancer cells and overcoming drug resistance. Zhu et al. reported a patient with advanced HCC who had a number of lung metastases that progressed during sorafenib treatment. SHR-1210 (an anti-PD-1 therapy) alone was used as a second-line treatment. Although lung metastasis did not decrease after 3 months of treatment, it declined noticeably and partially disappeared after 6 months of treatment. In addition, all lung metastases decreased continuously even after 17 months of treatment. Alpha-fetoprotein levels revealed a similar effect. After 19 months of follow-up, the patient was in good health. This suggests that SHR-1210 alone as a second-line therapy for HCC patients has a good antitumor effect. Modifying the tumor microenvironment with immune checkpoint blockade is an emerging and promising strategy in the field of HCC treatment (Fig. 6). The concept of immune checkpoint blockade is now being investigated to treat advanced tumors in adjuvant and neoadjuvant settings.

16Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are major causes of HCC in the Western and Eastern regions. The reactivation process of virus infection in the setting of chemotherapy and immunosuppression is likely to cause fulminant liver failure and death., Zuo et al. reported that a high viral load of HBV DNA is the critical correctable risk element in HCC recurrence. Researchers began to look at the correlations between sorafenib efficacy and viral reactivation, but opinions remain controversial. Two recently conducted studies reported that sorafenib blocked HCV infection by altering the viral entry step and the production of viral particles. In addition, sorafenib led to modification of claudin-1 expression and localization, which could partly be responsible for the anti-HCV effect., The opposite was shown in another study: combined application of sorafenib and interferon-α as an antiviral treatment was not beneficial. Moreover, Zhang and colleagues reported that sorafenib promoted virus reactivation by significantly reducing the number of natural killer (NK) cells and inhibiting the reactivity of NK cells against HCC cells. Lin et al. reported that targeting MYH9 noticeably promoted the survival of HCC-bearing mice and promoted sorafenib sensitivity of HCC cells in vivo. HBV X protein (HBX) interacted with MYH9 and triggered its expression through the modulation of GSK3β/β-catenin/c-Jun signaling. Witt-Kehati et al. reported that inhibition of pMAPK14 overturned resistance to sorafenib in hepatoma cells with HBV. The phosphorylated form of the pro-oncogenic protein mitogen-activated protein kinase 14 (pMAPK14) was triggered in sorafenib-treated hepatoma cells and related to HBV X protein expression. Therefore, there is no consensus on the correlation between viral reactivation and sorafenib therapy.

17Some diverse studies have indicated that sorafenib suppresses the EMT process. KPNA3, KIAA1199, and CDK1 were markedly elevated in SR cells and positively related to a high risk of recurrence and metastasis and advanced TNM stage in patients with HCC. All of them were found to trigger EMT and are involved in EGFR phosphorylation and the AKT-ERK signaling cascade.– Blocking these genes may improve sorafenib antitumor responses, providing a rational combination treatment to increase sorafenib efficacy (Table 5).,– It has been recently shown that cancer stem cells (CSCs) also participate in therapeutic resistance in HCC. CSC markers act as predictors in the response to sorafenib. Overexpression of the CSC markers CD90 and CD133 in HCC was related to a poorer response to sorafenib than normal expression of these markers (Table 5). Protein tyrosine kinase 2 (PTK2) was found to activate CSC traits and drive tumorigenicity by facilitating the nuclear accumulation of β-catenin in HCC cells, leading to sorafenib resistance. Xiao et al. reported that hypoxia is likely to enrich the HCC CSC population by changing AR/miR-520f-3p/SOX9 signaling, and targeting of this affected signaling by the small molecule miR-520f-3p could facilitate novel therapy to more effectively restrain HCC progression. These studies will help motivate researchers to explore sorafenib resistance and help develop effective strategies for the treatment of HCC in the clinic. Apart from this, several studies on sorafenib resistance in HCC have been reported (Table 5);– however, the mechanism is not within the scope of this review. For example, Haga et al. found that overexpression of c-Jun contributed to sorafenib resistance in human hepatoma cell lines. The activation of JNK and high CD133 expression levels predicted an ineffective response to sorafenib in HCC. Downregulation of TGF-β expression reversed the sorafenib resistance of HCC cells.

18Novel combination strategies including sorafenib and cytotoxic drugs have been studied to overcome resistance to sorafenib and to more effectively treat intermediate and advanced HCC. Wang et al. reported that sequential treatment with sorafenib and irinotecan was significantly better than monotherapy at inhibiting the growth of HepG2 xenografts. Sequential treatment with sorafenib and irinotecan noticeably elevated the levels of cleaved caspase-8, cleaved caspase-3, and PARP in HepG2 cells. Sorafenib inhibits p53 expression at both the mRNA and protein levels, which may facilitate cell cycle arrest and sensitization of tumor cells to irinotecan. Sequential therapy with sorafenib and irinotecan enhanced the efficacy of the two drugs alone in inducing apoptosis of HepG2 cells in vitro and inhibiting the growth of xenograft HepG2 cells in vivo. Although the addition of sorafenib to adriamycin did not significantly delay progression, the median survival time associated with sorafenib plus adriamycin was significantly longer than that associated with adriamycin alone in terms of overall survival and progression-free survival. In recent years, it has been reported that the liquid-gas phase transformation of sorafenib/doxorubicin-nanodroplets (SF/DOX-NDs) can be used as cavitation nuclei to promote drug release and increase cell uptake after therapeutic ultrasound (TUS) irradiation. In addition, this strategy can also induce the apoptosis of HCC cells and suppress HCC cell proliferation, migration and invasion, suggesting that SF/DOX-ND combination treatment may be a low-side effect and effective treatment for HCC. In addition, it was found that GEMOX based on sorafenib as a first-line medical treatment followed by sorafenib as maintenance therapy exhibited high performance with manageable toxicity for HCC patients in the late stage. Regarding the mechanism, a recent study showed that NOD2 made HCC cells noticeably more susceptible to sorafenib, lenvatinib and 5-FU treatment by activating the AMPK pathway to trigger apoptosis. Slit3 repression triggered chemoresistance to sorafenib, oxaliplatin and 5-FU via cyclin D3 and by enxtending survival and inhibiting β-catenin degradation. However, the different pharmacokinetic characteristics, hydrophobicity, and systemic toxicity of these drugs present serious challenges to the clinical application of this combination therapy. The efficacy and safety of some cytotoxic chemotherapy drugs are still being determined in phase III clinical trials, and the clinical use of cytotoxic chemotherapy drugs in combination with sorafenib requires further research.

19EGF and EGFR are critical to the development of HCC, and strategies targeting EGFR are able to overcome sorafenib resistance. In clinical practice, in addition to anti-EGFR antibodies (e.g., cetuximab), there are also TKIs targeting EGFR. According to some preclinical studies, cetuximab alone or in combination can inhibit HCC cell proliferation.– Nevertheless, in one phase II study, cetuximab therapy did not show encouraging results. One study explored the performance of a combination of the anti-EGFR antibody cetuximab with oxaliplatin and capecitabine in late-stage HCC and showed that the capecitabine/oxaliplatin/cetuximab combination was tolerable, although there was a high rate of diarrhea. The combination was associated with only a modest response rate but a substantial α-fetoprotein (AFP) response and a high radiographically determined stable disease rate. The time to progression and overall survival were shorter than would be expected for treatment with sorafenib. In patients who received gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab therapy, the response rate reached 20%, while 40% of patients developed stable disease. Erlotinib is an EGFR-specific receptor tyrosine kinase inhibitor. Disappointingly, a recent phase III randomized, double-blind, placebo-controlled trial showed that sorafenib in combination with erlotinib had no beneficial effect on survival in late-stage HCC patients compared to sorafenib alone.

20Sorafenib suppresses the Raf/MAPK signaling pathway, whereas it can activate the PI3K/AKT pathway, suggesting an interaction between the MAPK/ERK pathway and the PI3K/AKT pathway. The potential compensation mechanism presented by the PI3K/AKT pathway can cause sorafenib resistance in HCC patients., Accordingly, by inhibiting the multiple pathways involved in HCC, a more effective survival outcome is likely to be achieved with a combination of targeted therapies. Liangtao Ye et al. found that copanlisib led to cell cycle arrest by affecting the cyclin D1/CDK4/6 signaling pathway, which significantly reduced cell activity and inhibited the colony forming process in various natural and sorafenib-resistant HCC cells. An increase in phosphorylated AKT was identified in cells being treated with sorafenib and was uniformly observed in 6 diverse clones of sorafenib-resistant cells that were not stimulated. Sorafenib plus copanlisib to treat HCC in the late stage is a reasonable potential therapy. Interestingly, the novel CDK4/6 inhibitors palbociclib and ribociclib, which were recently approved to treat hormone receptor-positive and HER2-negative breast cancer, both demonstrated antitumor activity in SR HCC cells and acted synergistically with sorafenib in HCC cell lines. Both agents induced cell cycle arrest in HCC cells that express Rb protein., Marozin et al. demonstrated that NSC74859, a specific inhibitor of signal transducer and activator of transcription 3 (STAT3), effectively inhibits the proliferation of HCC cells and is likely to be incorporated into vesicular stomatitis virus (VSV) oncolytic virus therapy. The protection of primary hepatocytes and nervous system cells from virus-triggered cytotoxic effects by NSC74859 increased the maximal tolerated dose of mouse VSV and enhanced the potential benefits of this combination therapy. The combination of sorafenib, which targets the PI3K/AKT/mTOR pathway, with PKI-587, which primarily targets the Ras/Raf/MAPK signaling pathway, outperformed single-agent therapy by blocking both signaling pathways. However, no evidence was found that sorafenib plus everolimus improves the efficacy compared with sorafenib alone. A combination of 5 mg everolimus with full-dose sorafenib is feasible but has been shown to be more toxic than sorafenib alone.

21Immune checkpoint blockade is a promising treatment for HCC. Immunotherapy drugs cannot undergo liver metabolization, and HCC has moderate immunogenicity. For these reasons, from a theoretical perspective, the pharmacokinetic characteristics of immunotherapies make them rational choices in HCC that will not cause serious hepatotoxicity. Therefore, the combination of immunotherapy drugs and sorafenib to treat HCC in the late stage represents a novel therapeutic approach. Wang et al. reported that a combination of sorafenib and an anti-PD-L1 monoclonal antibody (mAb) can be used to treat HCC. According to Chen and colleagues, anti-PD-1 therapy enhanced the antitumor immune response of HCC models. Immunotherapy combinations containing anti-PD-1 antibodies plus sorafenib showed good performance only when they contained another drug to simultaneously target the immunosuppressive and hypoxic characteristics of the microenvironment (e.g., an additional CXCR4-inhibiting element). Recent in vivo and in vitro results suggest that targeting CD47 with combinations including sorafenib results in a beneficial effect on patients with HCC. However, the effective use immunotherapy in HCC must fully consider the HCC-specific immune microenvironment and response.

22Resistance to systemic sorafenib therapy emerges early in HCC. To enhance the antitumor effect induced by sorafenib, it is urgent to understand its potential mechanism and identify therapeutic targets. This study comprehensively summarized the molecular, cellular, and microenvironmental mechanisms that are likely to collectively facilitate sorafenib resistance in HCC. Epigenetic biological processes, transport processes, regulated cell death, and the tumor microenvironment have been shown to be related to resistance to sorafenib. To maintain the efficacy of sorafenib against HCC, we need to examine treatments for initial or acquired drug resistance.